Takeda-partnered Shattuck nabs mighty $118M funding round for immunotherapy, autoimmune work

After getting off a $46 million series A in 2018, Texas-based biotech Shattuck Labs has followed up with a major $118 million second funding round.

This will be funneled into its two early-stage assets: SL-172154 (SIRPα-Fc-CD40L), a fusion protein that combines CD47 inhibition with CD40 co-stimulation, and SL-279252 (PD1-Fc-OX40L), Shattuck’s lead PD-1 being developed alongside Takeda, which penned a deal with the biotech back in 2017.